57 results about "Clostridium Infections" patented technology

The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention discloses recombinant epsilon protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant epsilon protein is (a) protein formed by amino acid sequences shown in SEQ ID No.2 or (b) protein formed by amino acid sequences from the 51 site to the 370 site in SEQ ID No.2 or fusion protein obtained by fusing protein tags on carboxyl terminals or / and amino terminals of the (a) protein or the (b) protein. After animals are immune to the recombinant epsilon protein, the animals can generate the high serum antibody level and can resist attack of clostridium perfringens. The recombinant epsilon protein is good in dissolvability and easy to purify and can be taken as a diagnostic antigen or prepared into a monoclonal antibody or used for further studying the protein function and the conformation relationship.

The invention discloses a recombinant lactobacillus for simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin, a construction method of the recombinant lactobacillus and an application. The recombinant lactobacillus takes the clostridium perfringens alpha, beta 1, beta 2 and epsilon exotoxin reconstructed from gene levels in a toxicity removal manner as immunogen, the reconstructed exotoxin completely loses pathogenicity and still retains immunogenicity, and the lactobacillus serves as a safe living bacterium carrier for transmitting and expressing immunizing antigens, so that the recombinant lactobacillus capable of simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin is acquired, and a gene engineering lactobacillus multi-valence subunit toxin oral immune preparation capable of effectively preventing infection of five serotype clostridium perfringens is prevented. The recombinant lactobacillus provides effective technical means for preventing infection of the clostridium perfringens.

The present invention provides the compound represented by formula (I), or its stereoisomer, or its salt, or its solvate, or its prodrug, or its metabolite. This type of compound can effectively inhibit the growth of Clostridium difficile bacteria, and has significant antibacterial activity. It has a very good application prospect in the medicine of disease complications.

This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and / or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.